Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The QIAGEN Clinical Insights (QCI) portfolio—including the widely adopted "QCI Interpret"—is the leading global clinical decision support software for next-generation sequencing (NGS) data interpretation in hereditary disease and oncology. It has processed over four million patient test cases globally with high accuracy and rapid turnaround times. The system leverages both expert curation and AI-powered machine curation to deliver actionable insights for precision medicine.
Recent milestones include European IVDR certification as a Class C Medical Device—the first such approval for an NGS interpretation platform covering both hereditary and oncology applications. Over 850,000 samples are processed annually by the system.
The parent company, Qiagen N.V., reported revenues of $1.97 billion in 2023 with more than 5800 employees worldwide as of March 2024.
No drug development pipeline; this entity provides enabling technology/software rather than therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on QCI.